Renovaro Biosciences Inc.

https://lnkd.in/eQXxWYrk We See Exciting Opportunities in Cancer Diagnosis and #AI Collaboration Coming with the Stargate Project: We had the opportunity to reflect on a few key points raised by Larry Ellison (CTO, Oracle) during the Stargate Project announcement that are highly relevant to our current work and future opportunities: 1. Healthcare data centers focusing on #CancerTreatment 2. AI-driven cancer detection from just a few drops of blood using #CellFreeDNA 3. #Cancer and #VaccineDevelopment 4. #mRNA-based vaccine creation within 48 hours of diagnosis, powered by #GeneticSequencing These advancements align closely with what we’re doing at #Renovaro: • Renovaro Cube has an established system for diagnosing #Cancer using small amounts of blood samples: an #innovation that mirrors cutting-edge work in #CancerDetection . • Renovaro Bio is already making strides in #CancerVaccine research. • We are advancing a #Biomarker and #GeneMutation detection platform (pending acquisition of #PredictiveOncology). • We also have an ongoing collaboration with #Nebul, who will provide the latest #HPCCluster, which plays a pivotal role in the #AI and #CloudBasedStorage requirements of projects like #Stargate. Renovaro is perfectly positioned, in terms of #Technology, location, and timing, to align with the #StargateProject .

✨ Important Update: Renovaro Completes First Milestone Payment with Predictive Oncology! ✨    We are thrilled to announce that Renovaro Biosciences Inc. (NASDAQ: RENB) has advanced the first tranche of financing to Predictive Oncology, Inc. (NASDAQ: POAI) to kick start the integration of cutting-edge AI/ML platform technologies and core laboratory capabilities across Europe and the United States.   This strategic collaboration adds Predictive's AI-driven drug discovery platform and extensive bio-bank of over 150,000 patient tumor samples to Renovaro's robust capabilities in artificial intelligence and multi-omic data analysis. Together, we are poised to commercialize innovative drug discovery and diagnostic platforms, significantly enhancing precision medicine in oncology.  David Weinstein, CEO of Renovaro, shared, “We are committed to building a world-class diagnostics and discovery company, and this first tranche of financing is a significant step toward our definitive agreement. By merging Predictive Oncology, BioSymetrics, and RenovaroCube, we'll create a comprehensive AI-driven solution for biomarker discovery and validation." Raymond Vennare, CEO of Predictive Oncology, added, “The recent acquisition of BioSymetrics and our push to launch ChemoFx in Europe marks a pivotal advancement. We have seen tremendous progress and expect to finalize our definitive agreement in the coming weeks.” With this merger, our goal is to redefine the landscape of biomarker discovery and drug development, ultimately improving outcomes for cancer patients worldwide. Stay tuned for more updates as we continue this exciting journey! Read more: https://lnkd.in/gADD89te #Renovaro #PredictiveOncology #BiomarkerDiscovery #PrecisionMedicine #AI #DrugDiscovery #HealthcareInnovation #EarlyCancerDetection

📣 We are excited to announce that BioSymetrics is merging with Renovaro Biosciences Inc. to advance AI-driven biomarker discovery and precision medicine. This merger combines BioSymetrics' proprietary AI platform, Elion, with Renovaro’s oncology and immunotherapy expertise and workflow to accelerate drug discovery and therapeutic development of precision medicine solutions for cancer and other critical disease areas. Read more about our merger here: https://lnkd.in/gznZefJU

I'm very excited to announce that BioSymetrics is joining forces with Renovaro Biosciences Inc. (NASDAQ: RENB) in a strategic merger to accelerate AI-driven biomarker discovery and precision medicine! This is a huge milestone, and I want to take a moment to recognize the incredible work and dedication of our team. Your passion and commitment have brought us to this moment, and I couldn’t be more grateful. At BioSymetrics, we’ve always believed in the power of AI to unlock breakthroughs in healthcare. This merger strengthens that vision, bringing together cutting-edge technology across disciplines to push the boundaries of what’s possible in biomarker discovery and drug development. I’m excited for this next phase and all the opportunities ahead! #AI #PrecisionMedicine https://lnkd.in/g6gaqdJJ

📣 We are excited to announce that BioSymetrics is merging with Renovaro Biosciences Inc. to advance AI-driven biomarker discovery and precision medicine. This merger combines BioSymetrics' proprietary AI platform, Elion, with Renovaro’s oncology and immunotherapy expertise and workflow to accelerate drug discovery and therapeutic development of precision medicine solutions for cancer and other critical disease areas. Read more about our merger here: https://lnkd.in/gznZefJU

🌟 Exciting News: Renovaro and #BioSymetrics Announce Definitive Merger Agreement! 🌟 We are excited to share that #Renovaro Biosciences Inc. (NASDAQ: RENB), a leader in TechBio focused on next-generation diagnostics and cancer therapies, has entered into a definitive merger agreement with #BioSymetrics, a pioneering company in AI-driven drug #discovery and #biomarker identification. This strategic combination aims to accelerate biomarker identification, enhance drug discovery processes, and expand applications of precision medicine in #cancer and beyond. At the heart of this collaboration is BioSymetrics’ state-of-the-art Elion platform, which utilizes #AI and machine learning to uncover complex #biological relationships, expediting the discovery of diagnostics and therapeutics. David Weinstein, CEO of Renovaro, emphasized, “This merger is a pivotal step in our mission to diagnose cancer and advance precision medicine. By merging our oncology expertise with BioSymetrics' innovative biomarker discovery capabilities, we are creating a powerful synergy that enhances our ability to identify new therapeutic targets and accelerate drug development.” Anthony Iacovone, CEO of BioSymetrics, added, “We are excited to join forces with Renovaro to translate cutting-edge biomarker discoveries into tangible advancements in drug development. Together, we can accelerate the journey from discovery to #clinical application.” With this merger, we will integrate AI-powered biomarker discovery with #innovative drug development strategies, ultimately bringing more precise and effective treatments to patients worldwide. The transaction is anticipated to close in March 2025, pending customary closing conditions and regulatory approvals. For further details, visit our websites: Renovaro (www.renovarogroup.com) and BioSymetrics (www.biosymetrics.com). Read More: https://lnkd.in/eNAjaq8Y #Renovaro #BioSymetrics #Merger #BiomarkerDiscovery #PrecisionMedicine #DrugDiscovery #AI #HealthcareInnovation #EarlyCancerDetection #RenovaroBiosciencesInc

🚀 Exciting news from #Renovaro Inc.! We are thrilled to announce that we have secured $15 million in additional equity, committed at a share price of $1.00, along with a privately placed cash warrant exercisable at $1.50 with a one-year term. David Weinstein, our Chief Executive Officer, stated, “This new capital empowers us to accelerate our mission to revolutionize healthcare by integrating advanced diagnostics and personalized #immunotherapy. Our focus is on early #diagnosis, improved targeted treatments, and innovative drug discovery." The future of #cancer diagnostics and therapeutics is bright, and we’re proud to be at the forefront of this transformative journey! 🌟 #Renovaro #CancerDiagnostics #Immunotherapy #Innovation #Healthcare #AI #Investment #Funding #RenovaroBiosciences Read More: https://lnkd.in/eTdjQsnp